GSK
Strong BuyUnloved QualityGSK plc · Healthcare · United Kingdom · $99.6B cap · $243.0M/day traded
$50.02 -1.2% · close 21 Oct · scored 22 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Report expected 28 Oct: the next-year EPS estimate has fallen 4.6% over the last 13 weeks.
As of 22 Oct 2026, MoatMap's StockRank for GSK plc (GSK) is 82/100, ranked against 24,000+ stocks in 35 markets (Quality 72, Value 64, Momentum 42, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT GSK PLC
Read
GSK plc is a global biopharmaceutical giant focused on the research, development, and commercialization of innovative vaccines and specialty medicines. The company holds a dominant market position in the global vaccine industry and is a leader in HIV therapeutics through its majority-owned ViiV Healthcare joint venture. Following the spin-off of its consumer healthcare division, GSK operates as a pure-play, research-driven healthcare leader with robust R&D pipelines in infectious diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.2B | 40.6B | 42.0B | 43.7B | 3.7% | 44.3B | 45.4B | 47.5B | 4.3% |
| EPS | 20.31 | 6.59 | 3.44 | 7.56 | -28.1% | 3.17 | 7.57 | 7.90 | 2.2% |
| Shares | 2.0B | 2.0B | 2.0B | 2.0B | 0.0% | 2.0B | — | — | — |
| Debt | 28.1B | 24.1B | 22.7B | 23.7B | -5.5% | 24.4B | — | — | — |
| Equity | 14.2B | 17.9B | 18.3B | 21.9B | 15.6% | — | — | — | — |
| Op CF | 9.9B | 9.1B | 8.8B | 10.4B | 1.5% | 11.1B | — | — | — |
| Inv CF | -11.7B | -2.1B | -1.6B | -5.7B | — | — | — | — | — |
| Fin CF | 1.1B | -7.5B | -6.3B | -4.9B | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 80% of stocks we rank over the past year (26% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GSK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GSK | GSK plc(you) | $99.6B | 82 | Strong Buy |
| SAN.PA | Sanofi | $99.7B | 89 | Strong Buy |
| PFE | Pfizer Inc. | $160.6B | 84 | Strong Buy |
| NVO | Novo Nordisk A/S | $168.6B | 85 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $187.7B | 79 | Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.2B | 78 | Buy |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $69.4B | 72 | Buy |
| NVS | Novartis AG | $271.3B | 82 | Strong Buy |
| BRM.DE | Bristol-Myers Squibb Company | $121.2B | 99 | Strong Buy |
| IDP.DE | Biogen Inc. | $32.9B | 82 | Strong Buy |
Peer medians: ROE 3.0% · P/E 23.9x · Gross margin 53.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.